Short list of PEER REVIEW PAPERS THAT VERIFY THE DATA FROM accused misconduct by Dr Carlo Croce

1. Wang H, Xu C, Kong X, Li X, Kong X, Wang Y, Ding X, Yang Q. Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer. PLoS One. 2014 Jun 6;9(6):e99067. doi: 10.1371/journal.pone.0099067. Erratum in: PLoS One. 2019 Mar 21;14(3):e0214433. PMID: 24905916; PMCID: PMC4048247.
2. Li B, Lu Y, Yu L, Han X, Wang H, Mao J, Shen J, Wang B, Tang J, Li C, Song B. miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF-κB/COX-2 activation. Chem Biol Interact. 2017 Nov 1;277:33-42. doi: 10.1016/j.cbi.2017.08.014. Epub 2017 Aug 24. Erratum in: Chem Biol Interact. 2021 Aug 25;345:109556. PMID: 28844858.
3. Ma S, Sun J, Guo Y, Zhang P, Liu Y, Zheng D, Shi J. Combination of AAV-TRAIL with miR-221-Zip Therapeutic Strategy Overcomes the Resistance to TRAIL Induced Apoptosis in Liver Cancer. Theranostics. 2017 Jul 22;7(13):3228-3242. doi: 10.7150/thno.19893. PMID: 28900506; PMCID: PMC5595128.
4. Gong L, Zhang W, Yuan Y, Xing X, Li H, Zhao G. miR-222 promotes invasion and migration of ovarian carcinoma by targeting PTEN. Oncol Lett. 2018 Jul;16(1):984-990. doi: 10.3892/ol.2018.8743. Epub 2018 May 18. PMID: 29963173; PMCID: PMC6019905.
5. Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, Zhi-Fan J, Pei-Yu P, Qing-Yu Z, Chun-Sheng K. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer. 2010 Jul 12;10:367. doi: 10.1186/1471-2407-10-367. PMID: 20618998; PMCID: PMC2914702.
6. Di Martino MT, Arbitrio M, Caracciolo D, Cordua A, Cuomo O, Grillone K, Riillo C, Caridà G, Scionti F, Labanca C, Romeo C, Siciliano MA, D'Apolito M, Napoli C, Montesano M, Farenza V, Uppolo V, Tafuni M, Falcone F, D'Aquino G, Calandruccio ND, Luciano F, Pensabene L, Tagliaferri P, Tassone P. miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review. Mol Ther Nucleic Acids. 2022 Feb 11;27:1191-1224. doi: 10.1016/j.omtn.2022.02.005. PMID: 35282417; PMCID: PMC8891816. (300+ references)
7. Hou L, Tong X, Lin S, Yu M, Ye WC, Xie M. MiR-221/222 Ameliorates Deoxynivalenol-Induced Apoptosis and Proliferation Inhibition in Intestinal Epithelial Cells by Targeting PTEN. Front Cell Dev Biol. 2021 May 19;9:652939. doi: 10.3389/fcell.2021.652939. PMID: 34095117; PMCID: PMC8170406.
8. Di Paolo D, Pontis F, Moro M, Centonze G, Bertolini G, Milione M, Mensah M, Segale M, Petraroia I, Borzi C, Suatoni P, Brignole C, Perri P, Ponzoni M, Pastorino U, Sozzi G, Fortunato O. Cotargeting of miR-126-3p and miR-221-3p inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signalling. Mol Oncol. 2021 Nov;15(11):2969-2988. doi: 10.1002/1878-0261.13036. Epub 2021 Jul 21. PMID: 34107168; PMCID: PMC8564655.
9. Han J, Wang JZ, Yang X, Yu H, Zhou R, Lu HC, Yuan WB, Lu JC, Zhou ZJ, Lu Q, Wei JF, Yang H. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. Mol Cancer. 2019 Jun 22;18(1):110. doi: 10.1186/s12943-019-1036-9. PMID: 31228940; PMCID: PMC6588935.
10. Diao Y, Fu H, Wang Q. MiR-221 Exacerbate Cell Proliferation and Invasion by Targeting TIMP3 in Papillary Thyroid Carcinoma. Am J Ther. 2017 May;24(3):e317-e328. doi: 10.1097/MJT.0000000000000420. PMID: 27077469; PMCID: PMC5417575.
11. Yan Y, Xu Y, Ni G, Wang S, Li X, Gao J, Zhang H. MicroRNA-221 promotes proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs) by targeting tissue inhibitor of metalloproteinases-3 (TIMP3). Cardiovasc Diagn Ther. 2020 Aug;10(4):646-657. doi: 10.21037/cdt-20-328. PMID: 32968621; PMCID: PMC7487395.
12. Stadnik PS, Gilbert SJ, Tarn J, Charlton S, Skelton AJ, Barter MJ, Duance VC, Young DA, Blain EJ. Regulation of microRNA-221, -222, -21 and -27 in articular cartilage subjected to abnormal compressive forces. J Physiol. 2021 Jan;599(1):143-155. doi: 10.1113/JP279810. Epub 2020 Oct 31. PMID: 33052608; PMCID: PMC8132181.
13. Cheng YH, Chiang EI, Syu JN, Chao CY, Lin HY, Lin CC, Yang MD, Tsai SY, Tang FY. Treatment of 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 inhibits TNF-alpha-mediated expression of MMP-9 protein and cell invasion through the suppression of JNK pathway and microRNA 221 in human pancreatic adenocarcinoma cancer cells. PLoS One. 2021 Mar 17;16(3):e0247550. doi: 10.1371/journal.pone.0247550. PMID: 33730072; PMCID: PMC7968633.
14. Zibert JR, Løvendorf MB, Litman T, Olsen J, Kaczkowski B, Skov L. MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci. 2010 Jun;58(3):177-85. doi: 10.1016/j.jdermsci.2010.03.004. Epub 2010 Mar 17. PMID: 20417062.
15. Du L, Ma S, Wen X, Chai J, Zhou D. Oral squamous cell carcinoma cells are resistant to doxorubicin through upregulation of miR‑221. Mol Med Rep. 2017 Sep;16(3):2659-2667. doi: 10.3892/mmr.2017.6915. Epub 2017 Jul 4. PMID: 28677788; PMCID: PMC5547975.
16. Zhang C, Zhang J, Hao J, Shi Z, Wang Y, Han L, Yu S, You Y, Jiang T, Wang J, Liu M, Pu P, Kang C. High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med. 2012 Jun 8;10:119. doi: 10.1186/1479-5876-10-119. PMID: 22681957; PMCID: PMC3403924.
17. Gan R, Yang Y, Yang X, Zhao L, Lu J, Meng QH. Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Ther. 2014 Jul;21(7):290-6. doi: 10.1038/cgt.2014.29. Epub 2014 Jun 13. PMID: 24924200.
18. Brognara E, Fabbri E, Bazzoli E, Montagner G, Ghimenton C, Eccher A, Cantù C, Manicardi A, Bianchi N, Finotti A, Breveglieri G, Borgatti M, Corradini R, Bezzerri V, Cabrini G, Gambari R. Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR-221. J Neurooncol. 2014 May;118(1):19-28. doi: 10.1007/s11060-014-1405-6. Epub 2014 Mar 5. PMID: 24595467.
19. Chen D, Yan W, Liu Z, Zhang Z, Zhu L, Liu W, Ding X, Wang A, Chen Y. Downregulation of miR-221 enhances the sensitivity of human oral squamous cell carcinoma cells to Adriamycin through upregulation of TIMP3 expression. Biomed Pharmacother. 2016 Feb;77:72-8. doi: 10.1016/j.biopha.2015.12.002. Epub 2015 Dec 19. PMID: 26796268.
20. Xu Y, Bei Y, Shen S, Zhang J, Lu Y, Xiao J, Li X. MicroRNA-222 Promotes the Proliferation of Pulmonary Arterial Smooth Muscle Cells by Targeting P27 and TIMP3. Cell Physiol Biochem. 2017;43(1):282-292. doi: 10.1159/000480371. Epub 2017 Aug 30. PMID: 28854428.
21. Zhang Y, Yang J, Zhou X, Wang N, Li Z, Zhou Y, Feng J, Shen D, Zhao W. Knockdown of miR-222 inhibits inflammation and the apoptosis of LPS-stimulated human intervertebral disc nucleus pulposus cells. Int J Mol Med. 2019 Oct;44(4):1357-1365. doi: 10.3892/ijmm.2019.4314. Epub 2019 Aug 16. PMID: 31432092; PMCID: PMC6713428.
22. Zhou S, Zhang S, Wang Y, Yi S, Zhao L, Tang X, Yu B, Gu X, Ding F. MiR-21 and miR-222 inhibit apoptosis of adult dorsal root ganglion neurons by repressing TIMP3 following sciatic nerve injury. Neurosci Lett. 2015 Jan 23;586:43-9. doi: 10.1016/j.neulet.2014.12.006. Epub 2014 Dec 4. PMID: 25484256.
23. Shi C, Wu YY, Wei LQ. MiR-221 affects the proliferation and apoptosis of laryngeal cancer cells through the PI3K/AKT signaling pathway. Eur Rev Med Pharmacol Sci. 2020 Feb;24(3):1258-1263. doi: 10.26355/eurrev\_202002\_20180. PMID: 32096156
24. Hao C, Lu Z, Zhao Y, Chen Z, Shen C, Ma G, Chen L. Overexpression of GATA4 enhances the antiapoptotic effect of exosomes secreted from cardiac colony-forming unit fibroblasts via miRNA221-mediated targeting of the PTEN/PI3K/AKT signaling pathway. Stem Cell Res Ther. 2020 Jun 26;11(1):251. doi: 10.1186/s13287-020-01759-8. PMID: 32586406; PMCID: PMC7318537.
25. Xie Q, Yan Y, Huang Z, Zhong X, Huang L. MicroRNA-221 targeting PI3-K/Akt signaling axis induces cell proliferation and BCNU resistance in human glioblastoma. Neuropathology. 2014 Oct;34(5):455-64. doi: 10.1111/neup.12129. Epub 2014 Apr 30. PMID: 24780067
26. K, Elmi A, Barati M. Preliminary study on the effect of nucleolin specific aptamer-miRNA let-7d chimera on Janus kinase-2 expression level and activity in gastric cancer (MKN-45) cells. Mol Biol Rep. 2019 Feb;46(1):207-215. doi: 10.1007/s11033-018-4462-7. Epub 2018 Nov 10. PMID: 30415442.
27. Kumar S, Gomez EC, Chalabi-Dchar M, Rong C, Das S, Ugrinova I, Gaume X, Monier K, Mongelard F, Bouvet P. Integrated analysis of mRNA and miRNA expression in HeLa cells expressing low levels of Nucleolin. Sci Rep. 2017 Aug 21;7(1):9017. doi: 10.1038/s41598-017-09353-4. PMID: 28827664; PMCID: PMC5567140.
28. Kardani A, Yaghoobi H, Alibakhshi A, Khatami M. Inhibition of miR-155 in MCF-7 breast cancer cell line by gold nanoparticles functionalized with antagomir and AS1411 aptamer. J Cell Physiol. 2020 Oct;235(10):6887-6895. doi: 10.1002/jcp.29584. Epub 2020 Jan 31. PMID: 32003016.
29. San A, Palmieri D, Saxena A, Singh S. In silico study predicts a key role of RNA-binding domains 3 and 4 in nucleolin-miRNA interactions. Proteins. 2022 May 5. doi: 10.1002/prot.26355. Epub ahead of print. PMID: 35514080.
30. Bose S, Tholanikunnel TE, Reuben A, Tholanikunnel BG, Spicer EK. Regulation of nucleolin expression by miR-194, miR-206, and HuR. Mol Cell Biochem. 2016 Jun;417(1-2):141-53. doi: 10.1007/s11010-016-2721-2. Epub 2016 May 25. PMID: 27221739.
31. Jia W, Yao Z, Zhao J, Guan Q, Gao L. New perspectives of physiological and pathological functions of nucleolin (NCL). Life Sci. 2017 Oct 1;186:1-10. doi: 10.1016/j.lfs.2017.07.025. Epub 2017 Jul 24. PMID: 28751161.
32. Saleh AD, Cheng H, Martin SE, Si H, Ormanoglu P, Carlson S, Clavijo PE, Yang X, Das R, Cornelius S, Couper J, Chepeha D, Danilova L, Harris TM, Prystowsky MB, Childs GJ, Smith RV, Robertson AG, Jones SJM, Cherniack AD, Kim SS, Rait A, Pirollo KF, Chang EH, Chen Z, Van Waes C. Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer. Clin Cancer Res. 2019 May 1;25(9):2860-2873. doi: 10.1158/1078-0432.CCR-18-0716. Epub 2019 Feb 5. PMID: 30723145; PMCID: PMC6497577.
33. Cheng F, Pan Y, Lu YM, Zhu L, Chen S. RNA-Binding Protein Dnd1 Promotes Breast Cancer Apoptosis by Stabilizing the Bim mRNA in a miR-221 Binding Site. Biomed Res Int. 2017;2017:9596152. doi: 10.1155/2017/9596152. Epub 2017 Jan 16. PMID: 28191469; PMCID: PMC5278209.
34. Hussein S, Mosaad H, Rashed HE, El-Anwar MW. Up-regulated miR-221 expression as a molecular diagnostic marker in laryngeal squamous cell carcinoma and its correlation with Apaf-1 expression. Cancer Biomark. 2017 Jul 4;19(3):279-287. doi: 10.3233/CBM-160444. PMID: 28453462.
35. Ye Z, Hao R, Cai Y, Wang X, Huang G. Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer. Tumour Biol. 2016 Apr;37(4):4509-15. doi: 10.1007/s13277-015-4267-4. Epub 2015 Oct 26. PMID: 26503209
36. Zhou J, Hui X, Mao Y, Fan L. Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis. Biosci Rep. 2019 Aug 2;39(8):BSR20190625. doi: 10.1042/BSR20190625. PMID: 31311829; PMCID: PMC6680377.
37. Gu YF, Zhang H, Su D, Mo ML, Song P, Zhang F, Zhang SC. miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer. Chin Med J (Engl). 2013 Dec;126(23):4435-9. PMID: 24286402.
38. Larsen A, Meldgaard P, Sorensen B. Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients. Lung Cancer. 2019 Sep;135:92-96. doi: 10.1016/j.lungcan.2019.07.005. Epub 2019 Jul 12. PMID: 31447008.
39. Basuony SAHAE, Hamed RS. Anti-Micro RNA-221 a Promising Genetic Therapy of Oral Squamous Cell Carcinoma (SCC-25). Braz Dent J. 2020 Nov-Dec;31(6):634-639. doi: 10.1590/0103-6440202003350. PMID: 33237235.
40. Patel N, Garikapati KR, Makani VKK, Nair AD, Vangara N, Bhadra U, Pal Bhadra M. Regulating BMI1 expression via miRNAs promote Mesenchymal to Epithelial Transition (MET) and sensitizes breast cancer cell to chemotherapeutic drug. PLoS One. 2018 Feb 2;13(2):e0190245. doi: 10.1371/journal.pone.0190245. PMID: 29394261; PMCID: PMC5796693.
41. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, Newman RJ, Yue P, Bourgon R, Modrusan Z, Stern HM, Warming S, de Sauvage FJ, Amler L, Yeh RF, Dornan D. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci Signal. 2011 Jun 14;4(177):ra41. doi: 10.1126/scisignal.2001538. PMID: 21673316.
42. Zhao D, Yang Z, Chen C, Zhang Z, Yu Y, Li Z. CXCR4 promotes gefitinib resistance of Huh7 cells by activating the c-Met signaling pathway. FEBS Open Bio. 2021 Nov;11(11):3115-3125. doi: 10.1002/2211-5463.13305. Epub 2021 Oct 19. PMID: 34555268; PMCID: PMC8564344.
43. Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen YM, Chian CF, Liu X, Tan DSW, Bruns R, Straub J, Johne A, Scheele J, Park K, Yang JC; INSIGHT Investigators. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med. 2020 Nov;8(11):1132-1143. doi: 10.1016/S2213-2600(20)30154-5. Epub 2020 May 29. Erratum in: Lancet Respir Med. 2020 Jul;8(7):e59. PMID: 32479794.
44. Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, Chia V, Glaser S, Pultar P, Zhao S, Peng B, Akimov M, Tan DSW. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 Nov 1;36(31):3101-3109. doi: 10.1200/JCO.2018.77.7326. Epub 2018 Aug 29. Erratum in: J Clin Oncol. 2019 Jan 20;37(3):261. PMID: 30156984.
45. Ito T, Kumagai Y, Itano K, Maruyama T, Tamura K, Kawasaki S, Suzuki T, Murakami Y. Mathematical analysis of gefitinib resistance of lung adenocarcinoma caused by MET amplification. Biochem Biophys Res Commun. 2019 Apr 9;511(3):544-550. doi: 10.1016/j.bbrc.2019.02.086. Epub 2019 Feb 26. PMID: 30824185.
46. Sun X, Liu B, Zhao XD, Wang LY, Ji WY. MicroRNA-221 accelerates the proliferation of laryngeal cancer cell line Hep-2 by suppressing Apaf-1. Oncol Rep. 2015 Mar;33(3):1221-6. doi: 10.3892/or.2015.3714. Epub 2015 Jan 13. PMID: 25586265.